Truist Securities Maintains Buy on Axonics, Raises Price Target to $73
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Rescott has reaffirmed a Buy rating on Axonics (NASDAQ:AXNX) and increased the price target from $65 to $73, indicating a positive outlook on the company's stock.
December 22, 2023 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst David Rescott maintains a Buy rating on Axonics and raises the price target from $65 to $73, suggesting confidence in the company's future performance.
The increase in price target by Truist Securities reflects a bullish stance on Axonics, likely due to positive developments or expectations of strong performance. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100